-
癌症是导致人类死亡的主要原因之一,尽管近年在癌症的病因研究和新的诊断及治疗方法开发方面取得了重大进展,但恶性肿瘤的发病率和病死率仍然非常高。肿瘤的多药耐药(multidrug resistance,MDR)是指肿瘤细胞对化疗中常用的多种结构不相似和功能不同的药物的细胞毒性作用的共同抗性,即癌细胞表现出对多种化学治疗剂的交叉耐药性,是导致化疗失败的重要原因之一。早期预测肿瘤的耐药性并监测抗耐药治疗的疗效是临床需要解决的关键问题,其可以优化治疗方案,改善患者预后。分子影像技术可以利用分子探针靶向肿瘤细胞,实现对MDR肿瘤的早期监测,甚至可以帮助研究者对MDR机制和药物相互作用进行深入研究。在精准医疗时代,分子影像手段在肿瘤早期监测、制定治疗方案和疗效评估中起到了举足轻重的作用。本文将简述MDR的产生机制,并就分子影像技术在监测MDR方面的应用作一综述。
分子影像技术在多药耐药监测中的研究进展
The progress of molecular imaging in multidrug resistance
-
摘要: 肿瘤的多药耐药(MDR)是导致癌症复发和转移的重要因素。ATP结合盒转运蛋白(ABC转运蛋白)在人体广泛存在,并且ABC转运蛋白的过度表达是导致肿瘤细胞产生MDR的主要原因之一。利用分子影像技术对MDR肿瘤进行早期监测,有利于临床医师制定有效的治疗方案,并在一定程度上能改善肿瘤患者的预后。笔者就分子影像技术在监测MDR方面的研究进展进行简要综述。
-
关键词:
- 抗药性,多药 /
- 单光子发射计算机体层摄影术 /
- 正电子发射断层显像术 /
- ATP结合盒转运体 /
- 分子影像技术
Abstract: Tumor multidrug resistance (MDR) is an important factor that leads to cancer recurrence and metastasis. ATP-binding cassette transporters are widely present in humans, and their overexpression mainly induces MDR in tumor cells. Molecular imaging for the early monitoring of MDR tumors is helpful for clinicians to formulate effective treatment plans and improve tumor prognosis to a certain extent. This study briefly reviews the research progress on molecular imaging for MDR monitoring. -
[1] Morris ME, Rodriguez-Cruz V, Felmlee MA. SLC and ABC Transporters: Expression, Localization, and Species Differences at the Blood-Brain and the Blood-Cerebrospinal Fluid Barriers[J]. AAPS J, 2017, 19(5): 1317−1331. DOI: 10.1208/s12248−017−0110−8. [2] Aleksandra A,Falasca M, et al. ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?[J]. World J Gastroenterol, 2018, 24(29): 3222−3238. DOI: 10.3748/wjg.v24.i29.3222. [3] Juliano RL, Ling V. A Surface Glycoprotein Modulating Drug Permeability in Chinese Hamster Ovary Cell Mutants[J]. Biochim Biophys Acta, 1976, 455(1): 152−162. DOI: 10.1016/0005−2736(76)90160−7. [4] Mairinger S, Erker T, Müller M, et al. PET and SPECT Radiotracers to Assess Function and Expression of ABC Transporters In Vivo[J]. Curr Drug Metab, 2011, 12(8): 774−792. DOI: 10.2174/138920011798356980. [5] Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm[J]. Nat Rev Cancer, 2013, 13(10): 714−726. DOI: 10.1038/nrc3599. [6] Lin G, Mi P, Chu CC, et al. Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics[J/OL]. Adv Sci, 2016, 3(11): 1600134[2018-12-27]. 10.1002/advs.201600134">https://onlinelibrary.wiley.com/doi/full/10.1002/advs.201600134. DOI: 10.1002/advs.201600134. [7] Gomes BC, Honrado M, Armada AM, et al. ABC Efflux Transporters and the Circuitry of miRNAs: Kinetics of Expression in Cancer Drug Resistance[J]. Int J Mol Sci, 2020, 21(8): 2985. DOI: 10.3390/ijms21082985. [8] Fox E, Bates SE. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor[J]. Expert Rev Anticancer Ther, 2007, 7(8): 447−459. DOI: 10.15861/14737140.7.4.447. [9] Leopoldo M, Nardulli P, Contino M, et al. An updated patent review on P-glycoprotein inhibitors (2011-2018)[J]. Expert Opinion on Therapeutic Patents,, 2019, 29(6): 455−461. DOI: 10.1080/13543776.2019.1618273. [10] Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line[J]. Science, 1992, 258(5088): 1650−1654. DOI: 10.1126/science.1360704. [11] Chen YN, Mickley LA, Schwartz AM, et al. Characterization of Adriamycin-Resistant Human Breast Cancer Cells Which Display Overexpression of a Novel Resistance-Related Membrane Protein[J]. J Biol Chem, 1990, 265(17): 10073−10080. [12] Dean M, Rzhetsky A, Allikmets R. The Human ATP-Binding Cassette(ABC) Transporter Superfamily[J]. Genome Res, 2001, 11(7): 1156−1166. DOI: 10.1101/gr.184901. [13] Sivapackiam J, Harpstrite SE, Prior JL, et al. 67/68Galmydar: A metalloprobe for monitoring breast cancer resistance protein (BCRP)-mediated functional transport activity[J]. Nucl Med Biol, 2016, 43(3): 191−197. DOI: 10.1016/j.nucmedbio.2015.12.001. [14] Nakayama A, Matsuo H, Takada T, et al. ABCG2 is a High-Capacity Urate Transporter and its Genetic Impairment Increases Serum Uric Acid Levels in Humans[J]. Nucleosides Nucleotides Nucleic Acids, 2011, 30(12): 1091−1097. DOI: 10.1080/15257770.2011.633953. [15] Weidner LD, Zoghbi SS, Lu SY, et al. The Inhibitor Ko143 Is Not Specific for ABCG2[J]. J Pharmacol Exp Ther, 2015, 354(3): 384−393. DOI: 10.1124/jpet.115.225482. [16] Shen Y, Chen W, Zhao B, et al. CS1 is a novel topoisomerase IIα inhibitor with favorable drug resistance profiles[J]. Biochemical and Biophysical Research Communications, 2014, 453(3): 302−308. [17] Alpsoy A, Yasa S, Gündüz U. Etoposide resistance in MCF-7 breast cancer cell line is marked by multiple mechanisms[J]. Biomed Pharmacother, 2014, 68(3): 351−355. DOI: 10.1016/j.biopha.2013.09.007. [18] Huang F, Li SJ, Lu XH, et al. Two glutathione S-transferase inhibitors from Radix Angelicae sinensis[J]. Phytother Res, 2011, 25(2): 284−289. DOI: 10.1002/ptr.3197. [19] Mann A, Semenenko I, Meir M, et al. Molecular Imaging of Membrane Transporters' Activity in Cancer: a Picture is Worth a Thousand Tubes[J]. AAPS J, 2015, 17(4): 788−801. DOI: 10.1208/s12248−015−9752−6. [20] Sivapackiam J, Gammon ST, Harpstrite SE, et al. Targeted Chemotherapy in Drug-Resistant Tumors, Noninvasive Imaging of P-Glycoprotein-Mediated Functional Transport in Cancer, and Emerging Role of Pgp in Neurodegenerative Diseases[M]//Zhou J. Methods in Molecular Biology. Totowa: Humana Press, 2010: 141−181. DOI: 10.1007/978−1−60761−416−6_8. [21] Levchenko A, Mehta BM, Lee JB, et al. Evaluation of 11C-Colchicine for PET Imaging of Multiple Drug Resistance[J]. J Nucl Med, 2000, 41(3): 493−501. [22] Kannan P, Füredi A, Dizdarevic S, et al. In vivo characterization of [18F]AVT-011 as a radiotracer for PET imaging of multidrug resistance[J/OL]. Eur J Nucl Med Mol Imaging, 2019[2018-12-28]. https://link.springer.com/content/pdf/10.1007/s00259-019-04589-w.pdf. [published online ahead of print November 15, 2019]. DOI: 10.1007/s00259−019−04589−w. [23] Römermann K, Wanek T, Bankstahl M, et al. (R)--[11C]verapamil is selectively transported by murine and human P-glycoprotein at the blood–brain barrier, and not by MRP1 and BCRP[J]. Nucl Med Biol, 2013, 40(7): 873−878. DOI: 10.1016/j.nucmedbio.2013.05.012. [24] Bauer M, Wulkersdorfer B, Karch R, et al. Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[11C]verapamil in elderly vs. young subjects[J]. Bri J Clin Pharmacol, 2017, 83(9): 1991−1999. DOI: 10.1111/bcp.13301. [25] 陈伟君, 孙达. 99Tcm-MIBI显像在乳腺癌新辅助化疗中的应用价值[J]. 国际放射医学核医学杂志, 2015, 39(6): 487−492.
Chen WJ, Sun D. Clinical value of 99Tcm-MIBI imaging in neoadjuvant chemotherapy of breast cancer[J]. Int J Radiat Med Nucl Med, 2015, 39(6): 487−492.[26] Dizdarevic S, Peters AM. Imaging of multidrug resistance in cancer[J]. Cancer Imaging, 2011, 11(1): 1−8. DOI: 10.1102/1470−7330.2011.0001. [27] Fox E, Widemann BC, Pastakia D, et al. Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors[J]. Cancer Chemother Pharmacol, 2015, 76(6): 1273−1283. DOI: 10.1007/s00280−015−2845−10. [28] Borst P, Evers R, Kool M, et al. A Family of Drug Transporters: the Multidrug Resistance-Associated Proteins[J]. J Natil Cancer Inst, 2000, 92(16): 1295−1302. DOI: 10.1093/jnci/92.16.1295. [29] Nagengast WB, Oude Munnink TH, Dijkers EC, et al. Multidrug Resistance in Oncology and Beyond: From Imaging of Drug Efflux Pumps to Cellular Drug Targets[M]//Zhou J. Methods in Molecular Biology. Totowa: Humana Press, 2010: 15−31. DOI: 10.1007/978−1−60761−416−6_2. [30] Qawasmi I, Shmuel M, Eyal S. Interactions of ABCG2 (BCRP) with epidermal growth factor receptor kinase inhibitors developed for molecular imaging[J/OL]. Front Pharmacol, 2014, 5: 257[2018-12-27]. 10.3389/fphar.2014.00257/full">https://www.frontiersin.org/articles/10.3389/fphar.2014.00257/full. DOI: 10.3389/fphar.2014.00257. [31] Eadie LN, Hughes TP, White DL. Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib[J]. Clin Pharmacol Ther, 2014, 95(3): 294−306. DOI: 10.1038/clpt.2013.208. [32] Dörner B, Kuntner C, Bankstahl JP, et al. Synthesis and Small-Animal Positron Emission Tomography Evaluation of [11C]-Elacridar As a Radiotracer to Assess the Distribution of P-Glycoprotein at the Blood?Brain Barrier[J]. J Med Chem, 2009, 52(19): 6073−6082. DOI: 10.1021/jm900940f. [33] Kawamura K, Konno F, Yui J, et al. Synthesis and evaluation of [11C]XR9576 to assess the function of drug efflux transporters using PET[J]. Ann Nucl Med, 2010, 24(5): 403−412. DOI: 10.1007/s12149−010−0373−y. [34] Kannan P, Telu S, Shukla S, et al. The "Specific" P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2)[J]. ACS Chem Neurosci, 2011, 2(2): 82−89. DOI: 10.1021/cn100078a. [35] Mairinger S, Zoufal V, Wanek T, et al. Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice[J]. Eur J Pharm Sci, 2018, 115: 212−222. DOI: 10.1016/j.ejps.2018.01.034. [36] Kikuchi T, Okamura T, Okada M, et al. Benzyl [11C]Hippurate as an Agent for Measuring the Activities of Organic Anion Transporter 3 in the Brain and Multidrug Resistance-Associated Protein 4 in the Heart of Mice[J]. J Med Chem, 2016, 59(12): 5847−5856. DOI: 10.1021/acs.jmedchem.6b00454. [37] Okamura T, Kikuchi T, Fukushi K, et al. A novel noninvasive method for assessing glutathione-conjugate efflux systems in the brain[J]. Bioorg Med Chem, 2007, 15(9): 3127−3133. DOI: 10.1016/j.bmc.2007.02.045. [38] Galante E, Okamura T, Sander K, et al. Development of Purine-Derived 18F-Labeled Pro-drug Tracers for Imaging of MRP1 Activity with PET[J]. J Med Chem, 2014, 57(3): 1023−1032. DOI: 10.1021/jm401764a. [39] Okamura T, Kikuchi T, Okada M, et al. Noninvasive and Quantitative Assessment of the Function of Multidrug Resistance-Associated Protein 1 in the Living Brain[J]. J Cereb Blood Flow Metab, 2009, 29(3): 504−511. DOI: 10.1038/jcbfm.2008.135. [40] Wang MZ, Mao CQ, Wang H, et al. Molecular Imaging of P-Glycoprotein in Chemoresistant Tumors Using a Dual-Modality Pet/Fluorescence Probe[J]. Mol Pharmaceutics, 2017, 14(10): 3391−3398. DOI: 10.1021/acs.molpharmaceut.7b00420. [41] On NH, Chen F, Hinton M, et al. Assessment of P-Glycoprotein Activity in the Blood-Brain Barrier (BBB) Using Near Infrared Fluorescence (NIRF) Imaging Techniques[J]. Pharm Res, 2011, 28(10): 2505−2515. DOI: 10.1007/s11095−011−0478−6. [42] Semenenko I, Portnoy E, Aboukaoud M, et al. Evaluation of Near Infrared Dyes as Markers of P-Glycoprotein Activity in Tumors[J/OL]. Front Pharmacol, 2016, 7: 426[2018-12-27]. 10.3389/fphar.2016.00426/full">https://www.frontiersin.org/articles/10.3389/fphar.2016.00426/full. DOI: 10.3389/fphar.2016.00426. [43] Bakhsheshian J, Wei BR, Chang KE, et al. Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2[J]. Proc Natl Acad Sci USA, 2013, 110(51): 20801−20806. DOI: 10.1073/pnas.1312159110. [44] Sun Y, Gu MC, Zhu LX, et al. Gemcitabine upregulates ABCG2/BCRP and modulates the intracellular pharmacokinetic profiles of bioluminescence in pancreatic cancer cells[J]. Anti-Cancer Drugs, 2016, 27(3): 183−191. DOI: 10.1097/CAD.0000000000000315. [45] Saito S, Obata A, Kashiwagi Y, et al. Dynamic Contrast-Enhanced MRI of the Liver in Mrp2-Deficient Rats Using the Hepatobiliary Contrast Agent Gd-EOB-DTPA[J]. Invest Radiol, 2013, 48(7): 548−553. DOI: 10.1097/RLI.0b013e3182856a06. [46] Noguchi K, Katayama K, Sugimoto Y. Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics[J]. Pharmgenomics Pers Med, 2014, 7: 53−64. DOI: 10.2147/PGPM.S38295.
计量
- 文章访问数: 3556
- HTML全文浏览量: 2874
- PDF下载量: 18